AC
NTLA icon

AXQ Capital’s Intellia Therapeutics NTLA Stock Holding History

AXQ Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Buy
+32,801
New +$459K 0.06% 452
2025
Q3 		– Sell
-30,335
Closed -$285K – 748
2025
Q2 		$285K Buy
+30,335
New +$249K 0.09% 377
2023
Q1 		– Sell
-12,633
Closed -$441K – 589
2022
Q4 		$441K Buy
+12,633
New +$601K 0.31% 114

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

AXQ Capital's NTLA Position: Q2 2026 in Review

AXQ Capital opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 32,801 shares worth $555K. The stake represents 0.06% of the portfolio and ranks #452 among its holdings. This is a return to the name: AXQ Capital previously reported a position in NTLA as recently as Q2 2025.

AXQ Capital first reported a position in NTLA in Q4 2022 and has held it in 3 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • AXQ Capital held 32,801 shares of Intellia Therapeutics worth $555K as of Q2 2026.
  • Intellia Therapeutics was a new AXQ Capital position in Q2 2026.
  • Intellia Therapeutics made up 0.06% of AXQ Capital's portfolio in Q2 2026, its #452 holding.
  • AXQ Capital first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.